EUVIMEDScopri EUVIMED
ÜbersichtsarbeitOpen access

Ocular Gene Therapy: An Overview of Viral Vectors, Immune Responses, and Future Directions

Lamprini Banou, Soshian Sarrafpour, Christopher C Teng, Ji Liu

The Yale Journal of Biology and Medicine · 2024

DOI: 10.59249/hwid7537 ↗

At a glance

Übersichtsarbeit in The Yale Journal of Biology and Medicine, 2024. Written by Lamprini Banou and 3 co-authors. Institution: Department of Ophthalmology, University of Thessaly, Larissa, Greece. Major MEDLINE topics: Genetic Therapy, Genetic Vectors, Eye Diseases. Cited 26 times so far (Crossref). The full text is freely available in PubMed Central.

AbstractSubjectsDati bibliograficiCiteRelated studies

Abstract (original language)

Ocular gene therapy has rapidly advanced from proof-of-concept studies to clinical trials by exploiting the unique advantages of the eye, including its easy accessibility, relative immune privilege, and the ability to use the contralateral eye as a control. An important step forward was achieved with the Food and Drug Administration (FDA) approval of voretigene neparvovec (Luxturna) for the treatment of biallelic RPE65-mutation-associated retinal dystrophies in 2017. Gene therapy is a promising field aimed at treating various inherited and acquired eye diseases. Viral vectors such as adeno-associated virus (AAV) are mainly used to efficiently deliver genes. Despite the immune-privileged status of the eye, viral vector-based therapies can induce immune responses, potentially leading to gene therapy-associated uveitis. Future directions include developing strategies to reduce immune responses while maintaining therapeutic efficacy, optimizing vector selection, and improving delivery techniques. Continued advances in the field of viral vectors, particularly AAV, are expanding the potential applications of gene therapy to treat a variety of ocular diseases. To fully realize the potential of ocular gene therapy, more research and clinical trials are needed to improve these methods, ensure safe and efficient treatments, and ultimately overcome existing obstacles.

Subjects

MeSH terms (MEDLINE)

Genetic TherapyGenetic VectorsEye DiseasesHumansDependovirusAnimals

Author keywords

delivery routesimmune responsesocular applicationsocular gene therapyviral vectors

Authors and institutions

  • Department of Ophthalmology, University of Thessaly, Larissa, Greece.
  • Department of Ophthalmology and Visual Science, Yale School of Medicine, New Haven, CT, USA.

Cite

APA

Banou, L., Sarrafpour, S., Teng, C. C., & Liu, J. (2024). Ocular Gene Therapy: An Overview of Viral Vectors, Immune Responses, and Future Directions. The Yale Journal of Biology and Medicine. https://doi.org/10.59249/hwid7537

Vancouver

Banou L, Sarrafpour S, Teng CC, Liu J. Ocular Gene Therapy: An Overview of Viral Vectors, Immune Responses, and Future Directions. The Yale Journal of Biology and Medicine. 2024. doi:10.59249/hwid7537

BibTeX
@article{Banou2024,
  author = {Banou, Lamprini and Sarrafpour, Soshian and Teng, Christopher C and Liu, Ji},
  title = {Ocular Gene Therapy: An Overview of Viral Vectors, Immune Responses, and Future Directions},
  journal = {The Yale Journal of Biology and Medicine},
  year = {2024},
  doi = {10.59249/hwid7537}
}
Start for free →